BioArctic AB (publ) (BRCTF)
OTCMKTS
· Delayed Price · Currency is USD
19.00
+0.52 (2.81%)
Apr 23, 2025, 3:09 PM EDT
BioArctic AB Revenue
In the year 2024, BioArctic AB had annual revenue of 257.35M SEK, down -58.22%. BioArctic AB had revenue of 101.24M in the quarter ending December 31, 2024, with 1,269.72% growth.
Revenue
257.35M SEK
Revenue Growth
-58.22%
P/S Ratio
73.31
Revenue / Employee
2.41M SEK
Employees
107
Market Cap
1.70B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.38M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
BioArctic AB News
- 23 days ago - The European Commission refers lecanemab decision to Appeal Committee - PRNewsWire
- 4 weeks ago - BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference - PRNewsWire
- 5 weeks ago - BioArctic receives Orphan Drug Designation for exidavnemab the US - PRNewsWire
- 7 weeks ago - Therapeutic Goods Administration decides not to register lecanemab in Australia - PRNewsWire
- 7 weeks ago - The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU - PRNewsWire
- 2 months ago - Leqembi® sales reaches €200 million - first sales milestone achieved - PRNewsWire
- 3 months ago - FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US - Benzinga
- 3 months ago - FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US - PRNewsWire